Wnt/β-catenin signaling mediates antineoplastic effects of imatinib mesylate (Gleevec) in anaplastic thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 1, 2006, Pages 159-168

  Rao, Annavarapu Srinivas ^a   Kremenevskaja, Natalia ^a   Von Wasielewski, Reinhard ^a   Jakubcakova, Vladimira ^b   Kant, Shashi ^a   Resch, Julia ^a   Brabant, Georg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BETA CATENIN; CYCLIN D1; IMATINIB; LYMPHOID ENHANCER FACTOR 1; T CELL FACTOR PROTEIN; UVOMORULIN; WNT PROTEIN;

ANAPLASTIC THYROID CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL JUNCTION; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROID CELL; TIME; TISSUE MICROARRAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA; CASPASE 3; CASPASE 7; CASPASES; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; FLUORESCENT ANTIBODY TECHNIQUE; GENES, REPORTER; HUMANS; IMMUNOPRECIPITATION; LAMININ; LUCIFERASES; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; PROTEOGLYCANS; PYRIMIDINES; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; THYMIDINE; THYROID NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 30344445367     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1381     Document Type: Article

References (50)

1. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726
2. Heldin NE, Westermark B 1991 The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 3:127-131
3. Wiseman SM, Loree TR, Rigual NR, Hicks Jr WL, Douglas WG, Anderson GR, Stoler DL 2003 Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25:662-670
4. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH 2001 Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335-2342
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
6. Veness MJ, Porter GS, Morgan GJ 2004 Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 74:559-562
7. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM 1999 c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13:2400-2411
8. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346
9. Van Etten RA 1999 Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 9:179-186
10. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF 2005 Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646
11. Muller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwable J, Plewka S, Thomas M, Metzger R, Schneider PM, Brandts CH, Berdel WE, Serve H 2005 Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 65:1778-1782
12. Krystal GW, Honsawek S, Litz J, Buchdunger E 2000 The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326
13. Stephenson J 2000 Researchers buoyed by promise of targeted leukemia therapy. JAMA 283:317-321
14. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB 2000 Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145
15. Heldin NE, Gustavsson B, Claesson-Welsh L, Hammacher A, Mark J, Heldin CH, Westermark B 1988 Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proc Natl Acad Sci USA 85:9302-9306
16. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A 2002 Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484
17. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
18. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056
19. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423
20. von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Potter E, Brabant G, Georgii A 1997 Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57:2501-2507
21. Naito A, Iwase H, Kuzushima T, Nakamura T, Kobayashi S 2001 Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol 76:176-180
22. Huang SH, Wu JC, Chang KJ, Liaw KY, Wang SM 1999 Expression of the cadherin-catenin complex in well-differentiated human thyroid neoplastic tissue. Thyroid 9:1095-1103
23. Calautti E, Cabodi S, Stein PL, Hatzfeld M, Kedersha N, Paolo Dotto G 1998 Tyrosine phosphorylation and src family kinases control keratinocyte cell-cell adhesion. J Cell Biol 141:1449-1465
24. Herynk MH, Tsan R, Radinsky R, Gallick GE 2003 Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated β-catenin. Clin Exp Metastasis 20:291-300
25. Irby RB, Yeatman TJ 2002 Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 62:2669-2674
26. Kinch MS, Clark GJ, Der CJ, Burridge K 1995 Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J Cell Biol 130:461-471
27. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G 2001 β-Catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987-996
28. Fagman H, Larsson F, Arvidsson Y, Meuller J, Nordling M, Martinsson T, Helmbrecht K, Brabant G, Nilsson M 2003 Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation. Oncogene 22:6013-6022
29. Helmbrecht K, Kispert A, von Wasielewski R, Brabant G 2001 Identification of a Wnt/β-catenin signaling pathway in human thyroid cells. Endocrinology 142:5261-5266
30. Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT, Nieman MT, Fearon ER, Cho KR 2002 Role of β-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 160:1229-1238
31. Saldanha G, Ghura V, Potter L, Fletcher A 2004 Nuclear β-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 151:157-164
32. Nakashima M, Meirmanov S, Naruke Y, Kondo H, Saenko V, Rogounovitch T, Shimizu-Yoshida Y, Takamura N, Namba H, Ito M, Abrosimov A, Lushnikov E, Roumiantsev P, Tsyb A, Yamashita S, Sekine I 2004 Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant β-catenin expression. J Pathol 202:446-455
33. Karim R, Tse G, Putti T, Scolyer R, Lee S 2004 The significance of the Wnt pathway in the pathology of human cancers. Pathology 36:120-128
34. Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, Maeda S, Ichinose M, Kanematsu T, Yamashita S 2002 Aberrant localization of β-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433-3440
35. Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T, Brabant G 2005 Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24:2144-2154
36. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S 2003 The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896
37. Mitsiades CS, Sykoutri D, McMullan C, Poulaki V, Mitsiades N 2003 Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 88:5043-5044; author reply 5044
38. Dziba JM, Ain KB 2004 Imatinib mesylate (Gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 89:2127-2135
39. Podtcheko A OA, Namba H, Saenkob V, Yamashita S 2003 Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 88:5044
40. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL 2004 Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657-667
41. Zhou L, An N, Haydon RC, Zhou Q, Cheng H, Peng Y, Jiang W, Luu HH, Vanichakarn P, Szatkowski JP, Park JY, Breyer B, He TC 2003 Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the β-catenin signaling activity. Cancer Lett 193:161-170
42. Mauro MJ, Druker BJ 2001 STI571: targeting BCR-ABL as therapy for CML. Oncologist 6:233-238
43. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S 2002 Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62:188-199
44. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ 2000 Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195-3199
45. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J 2000 Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942
46. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401
47. Nagar B, Bommann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J 2002 Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243
48. Doggrell SA 2005 BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Investig Drugs 14:89-91
49. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW 2004 Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 4:285-299
50. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB 1996 Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104